Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 27, 2023

Iovance Biotherapeutics submits BLA to FDA for advanced melanoma drug lifileucel

Iovance Biotherapeutics has completed submission of the Biologics License Application (BLA) for lifileucel to the US Food and Drug Administration (FDA).

Continue
The slide shows melanoma on a patient's skin. Credit: Doc James / commons.wikimedia.org.
March 23, 2023

Dewpoint, Novo Nordisk to identify drug candidates for diabetic complications

Dewpoint’s discovery platform related to biomolecular condensates will help detect drug candidates for insulin resistance and diabetic complications. Credit: Dewpoint Therapeutics.
March 22, 2023

FDA grants fast track status to Prestige’s PBP1510 for pancreatic cancer

PBP1510 will mainly act on a tumour-specific protein called pancreatic adenocarcinoma upregulated factor. Credit: National Cancer Institute on Unsplash.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals March 16, 2023

Mediar Therapeutics announces $105m financing to advance fibrosis therapies

Pharmaceutical Business Review

Evergreen Theragnostics raises $15m from Series B round

invoX Pharma completes acquisition of F-star Therapeutics for $161m

Purple Biotech signs agreement to acquire Immunorizon

Popular

  1. Macomics signs collaboration deal with Ono Pharmaceutical
  2. FDA grants fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 to reduce triglycerides
  3. Orion receives approval from Chinese NMPA for darolutamide
  4. Everest gets Chinese approval for Xerava to treat cIAI
  5. China’s NMPA accepts GSK’s drug application review for Nucala to treat SEA

PRESS RELEASES

Join Us at DIA Europe 2023 – 22-24 March in Basel, Switzerland
Join Us at DIA Europe 2023 – 22-24 March in Basel, Switzerland
Pharmaceutical Business Review
Successful FDA Inspection at Gerresheimer Peachtree City, USA
Pharmaceutical Business Review
Gerresheimer: Identifying Counterfeit Cosmetics Products by Using a Smartphone
Pharmaceutical Business Review
300 Years of Gerresheimer Essen – Tradition and Progress Successfully Combined
Gerresheimer 2022: Profitable Growth Company Boosting Revenue and Adjusted EBITDA Growth to Double-Digit Levels
Gerresheimer 2022: Profitable Growth Company Boosting Revenue and Adjusted EBITDA Growth to Double-Digit Levels

Suppliers

Whitepapers

The Case for NMT in Life Sciences
The Case for NMT in Life Sciences
Usability Testing ‒ What, Why & Recent Results
Usability Testing ‒ What, Why & Recent Results
A Global Top Ten Pharma Client Saw Significant Spend Reduction Through the Use of RWS Managed Services
A Global Top Ten Pharma Client Saw Significant Spend Reduction Through the Use of RWS Managed Services